ES2251512T3 - Derivados de quinazolina como antagonista adrenergicos alfa-1. - Google Patents

Derivados de quinazolina como antagonista adrenergicos alfa-1.

Info

Publication number
ES2251512T3
ES2251512T3 ES01974210T ES01974210T ES2251512T3 ES 2251512 T3 ES2251512 T3 ES 2251512T3 ES 01974210 T ES01974210 T ES 01974210T ES 01974210 T ES01974210 T ES 01974210T ES 2251512 T3 ES2251512 T3 ES 2251512T3
Authority
ES
Spain
Prior art keywords
methyl
amino
alkyl
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01974210T
Other languages
English (en)
Spanish (es)
Inventor
Cyrus Kephra Becker
Chris Richard Melville
Juerg Roland Pfister
Xiaoming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2251512T3 publication Critical patent/ES2251512T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES01974210T 2000-08-31 2001-08-23 Derivados de quinazolina como antagonista adrenergicos alfa-1. Expired - Lifetime ES2251512T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22950300P 2000-08-31 2000-08-31
US229503P 2000-08-31

Publications (1)

Publication Number Publication Date
ES2251512T3 true ES2251512T3 (es) 2006-05-01

Family

ID=22861517

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01974210T Expired - Lifetime ES2251512T3 (es) 2000-08-31 2001-08-23 Derivados de quinazolina como antagonista adrenergicos alfa-1.

Country Status (19)

Country Link
US (1) US6559153B2 (enExample)
EP (1) EP1315714B1 (enExample)
JP (1) JP3971299B2 (enExample)
KR (1) KR100602929B1 (enExample)
CN (1) CN1308324C (enExample)
AR (1) AR032475A1 (enExample)
AT (1) ATE309240T1 (enExample)
AU (2) AU2001293788B2 (enExample)
BR (1) BR0113585A (enExample)
CA (1) CA2420177C (enExample)
DE (1) DE60114852T2 (enExample)
ES (1) ES2251512T3 (enExample)
GT (1) GT200100181A (enExample)
MX (1) MXPA03001777A (enExample)
PA (1) PA8527901A1 (enExample)
PE (1) PE20020407A1 (enExample)
UY (1) UY26919A1 (enExample)
WO (1) WO2002018348A2 (enExample)
ZA (1) ZA200301082B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE341552T1 (de) * 2001-08-10 2006-10-15 Neuro Therapeutics Ltd Derivate morphinähnlicher opioidverbindungen
JP2005521728A (ja) * 2002-04-03 2005-07-21 オリオン コーポレーション ＣＮＳ関連疾患のためのα２−アドレナリン受容体アンタゴニストの使用
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EA010852B1 (ru) * 2003-07-24 2008-12-30 Еуро-Селтик С. А. Пиперидиновые соединения и фармацевтические композиции, их содержащие
WO2006021345A2 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenergic alpha-1b receptor (adra1b)
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
DE602006010540D1 (de) * 2005-05-04 2009-12-31 Hoffmann La Roche (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008036700A2 (en) * 2006-09-19 2008-03-27 3M Innovative Properties Company Templated metal oxide particles and methods of making
CA2701057C (en) 2007-10-11 2015-03-24 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
ES2761311T3 (es) 2011-04-01 2020-05-19 Astrazeneca Ab Tratamiento terapéutico
SMT201900708T1 (it) 2011-11-30 2020-01-14 Astrazeneca Ab Trattamento di combinazione di un cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CA3055215A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
WO2019088095A1 (ja) * 2017-11-02 2019-05-09 国立大学法人九州大学 鎮痛剤及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997011698A1 (en) 1995-09-29 1997-04-03 Merck & Co., Inc. ALPHA 1b ADRENERGIC RECEPTOR ANTAGONISTS
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6355641B1 (en) 1999-03-17 2002-03-12 Syntex (U.S.A.) Llc Oxazolone derivatives and uses thereof

Also Published As

Publication number Publication date
WO2002018348A3 (en) 2002-07-11
ZA200301082B (en) 2004-05-07
GT200100181A (es) 2002-05-23
DE60114852D1 (de) 2005-12-15
US6559153B2 (en) 2003-05-06
CA2420177A1 (en) 2002-03-07
AU9378801A (en) 2002-03-13
JP3971299B2 (ja) 2007-09-05
WO2002018348A2 (en) 2002-03-07
UY26919A1 (es) 2002-02-28
CA2420177C (en) 2008-07-08
JP2004507527A (ja) 2004-03-11
EP1315714A2 (en) 2003-06-04
AR032475A1 (es) 2003-11-12
US20020045614A1 (en) 2002-04-18
ATE309240T1 (de) 2005-11-15
PE20020407A1 (es) 2002-05-21
BR0113585A (pt) 2003-07-29
DE60114852T2 (de) 2006-07-27
KR20030022421A (ko) 2003-03-15
KR100602929B1 (ko) 2006-07-20
MXPA03001777A (es) 2003-06-04
CN1545510A (zh) 2004-11-10
EP1315714B1 (en) 2005-11-09
AU2001293788B2 (en) 2007-10-11
PA8527901A1 (es) 2002-07-30
CN1308324C (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
ES2251512T3 (es) Derivados de quinazolina como antagonista adrenergicos alfa-1.
ES2241891T3 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b.
US7320989B2 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
ES2315390T3 (es) Piperazinas sustituidas como moduladores del receptor de melanocortina.
AU2001260310B2 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
US20080004312A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
DE60114413T2 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
SK15852000A3 (sk) Derivát 1-[(1-substituovaného-4-piperidinyl)metyl]-4-piperidínu, spôsob jeho prípravy, farmaceutický prípravok obsahujúci tento derivát a medziprodukt tohto derivátu
AU2001293788A1 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
JP2000512645A (ja) スルホンアミド誘導体およびｃｎｓ障害の治療におけるそれらの使用
ES2310032T3 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina como antagonistas de receptores muscarinicos.
KR100686757B1 (ko) 2,4-치환된 인돌 및 그의 5-ｈｔ6 조절제로서 용도
ES2290726T3 (es) Derivados de quinazolina 5-sustituidos.
KR100687992B1 (ko) 무스카린 수용체 길항제로서 4-피페리딘일 알킬아민 유도체
ES2208947T3 (es) Derivados de piperazino como antagonistas de neuroquinina.
ES2297029T3 (es) Derivados de aminotetralina como antagonistas de receptores muscarinicos.
US6355641B1 (en) Oxazolone derivatives and uses thereof
KR20110080181A (ko) 3-(벤질아미노)-피롤리딘 유도체 및 이의 ｎｋ-3 수용체 길항제로서의 용도
ES2244243T3 (es) Deerivados de quinazolinona.
KR100777876B1 (ko) 프로스타글란딘 ｉ2(ｉｐ) 길항제로서 이미다졸린-2-일아미노페닐 아마이드
AU2004255338A1 (en) Thiophenylaminoimidazolines as prostaglandin I2 antagonists